Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma

Journal of Hematology and Oncology

Volumn 10, Issue 1, 2017, Pages 1-11

  Feng, Kai chao ^a   Guo, Ye lei ^a   Liu, Yang ^a   Dai, Han ren ^a   Wang, Yao ^a   Lv, Hai yan ^a   Huang, Jian hua ^a   Yang, Qing ming ^a   Han, Wei dong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

CART cocktail immunotherapy; CD133; Cholangiocarcinoma; EGFR

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CA 19-9 ANTIGEN; CD133 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETANERCEPT; IMMUNOGLOBULIN; INTERLEUKIN 6; METHYLPREDNISOLONE; NIVOLUMAB; PACLITAXEL; TUMOR NECROSIS FACTOR; EGFR PROTEIN, HUMAN;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; ARTICLE; BILE DUCT CARCINOMA; BILIARY STENT; BILIARY TRACT DRAINAGE; BILIARY TRACT INFECTION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CASE REPORT; CHILL; CHOLESTASIS; CONGESTIVE RASH; CYTOKINE INDUCED KILLER CELL; CYTOKINE RELEASE SYNDROME; CYTOTOXICITY; DISEASE SEVERITY; FATIGUE; FEMALE; FEVER; GASTROSCOPY; GENE DOSAGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; JAUNDICE; LAPAROTOMY; LICHEN STRIATUS; LIVER ABSCESS; LIVER CAUDATE LOBE; LYMPH NODE METASTASIS; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MIDDLE AGED; MONOTHERAPY; MUSCLE SORENESS; MYALGIA; PALLIATIVE THERAPY; PERITONEUM ADHESION; POORLY DIFFERENTIATED ADENOCARCINOMA; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROTEIN EXPRESSION; RASH; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RETROPERITONEAL CANCER; SUBCUTANEOUS HEMORRHAGE; T LYMPHOCYTE; TOMOTHERAPY; TUMOR GROWTH; UPPER ABDOMINAL PAIN; VOMITING; ADOPTIVE IMMUNOTHERAPY; BILE DUCT TUMOR; CLINICAL TRIAL; PROCEDURES; REMISSION; TREATMENT OUTCOME;

AC133 ANTIGEN; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; REMISSION INDUCTION; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 85008425546     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-016-0378-7     Document Type: Article

References (38)

1. Nataliya R, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383:2168-79.
2. Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015;29(2):221-32.
3. Ciombor KK, Goff LW. Advances in the management of biliary tract cancers. Clin Adv Hematol Oncol. 2013;11(1):28-34.
4. Merla A, Liu KG, Rajdev L. Targeted therapy in biliary tract cancers. Curr Treat Options Oncol. 2015;16(10):48.
5. Onesti CE, Romiti A, Roberto M, Falcone R, Marchetti P. Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure. Expert Rev Anticancer Ther. 2015;15(10):1183-98.
6. Dai H, Zhang W, Li X, Han Q, Guo Y, Zhang Y, et al. Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncoimmunology. 2015;4(11):e1027469.
7. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509-18.
8. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.
9. Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013;122:4129-39.
10. Dai H, Wang Y, Lu X, Han W. Chimeric antigen receptors modified T-cells for cancer therapy. J Natl Cancer Inst. 2016; 108(7). doi: 10.1093/jnci/djv439.
11. Maus MV, June CH. Making better chimeric antigen receptors for adoptive T-cell therapy. Clin Cancer Res. 2016;22(8):1875-84.
12. Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardière C, Boucher E, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014;15(8):819-28.
13. Feng K, Guo Y, Dai H, Wang Y, Li X, Jia H, et al. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. Sci China Life Sci. 2016;59(5):468-79.
14. Liu H, Lv L, Yang K. Chemotherapy targeting cancer stem cells. Am J Cancer Res. 2015;5(3):880-93.
15. Romano M, De Francesco F, Gringeri E, Giordano A, Ferraro GA, Di Domenico M, et al. Tumor microenvironment versus cancer stem cells in cholangiocarcinoma: synergistic effects? J Cell Physiol. 2016;231(4):768-76.
16. Schmohl JU, Vallera DA. CD133, Selectively targeting the root of cancer. Toxins. 2016;8(6). doi:10.3390/toxins8060165..
17. McGinley L, McMahon J, Strappe P, Barry F, Murphy M, O’Toole D, et al. Lentiviral vector mediated modification of mesenchymal stem cells & enhanced survival in an in vitro model of ischaemia. Stem Cell Res Ther. 2011;2(2):12.
18. Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139.
19. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011;118(23):6050-6.
20. Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123-38.
21. Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2015;21(4):687-92.
22. Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8(328):328rv324.
23. Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, et al. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res. 2014;20(16):4262-73.
24. Palazon A, Aragones J, Morales-Kastresana A, de Landazuri MO, Melero I. Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res. 2012;18(5):1207-13.
25. Bernstein MB, Krishnan S, Hodge JW, Chang JY. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol. 2016;13(8):516-24.
26. Shahabi V, Postow MA, Tuck D, Wolchok JD. Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy. Am J Clin Oncol. 2015;38(1):90-7.
27. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925-31.
28. Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumors: a proof-of-principle trial. Lancet Oncol. 2015;16(7):795-803.
29. John LB, Kershaw MH, Darcy PK. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology. 2013;2(10):e26286.
30. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275-87.
31. Kokuryo T, Yokoyama Y, Nagino M. Recent advances in cancer stem cell research for cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2012;19(6):606-13.
32. Leelawat K, Thongtawee T, Narong S, Subwongcharoen S, Treepongkaruna SA. Strong expression of CD133 is associated with increased cholangiocarcinoma progression. World J Gastroenterol. 2011;17(9):1192-8.
33. Shien K, Toyooka S, Ichimura K, Soh J, Furukawa M, Maki Y, et al. Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy. Lung Cancer. 2012;77(1):162-7.
34. Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 2013;5(197):197ra103.
35. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.
36. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321-30.
37. Caruso HG, Hurton LV, Najjar A, Rushworth D, Ang S, Olivares S, et al. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Res. 2015;75(17):3505-18.
38. Beatty GL, O’Hara M. Chimeric antigen receptor-modified T cells for the treatment of solid tumors: defining the challenges and next steps. Pharmacol Ther. 2016;166:30-9.